

## Disclosure of total number of voting rights and number of shares in the capital as of May 31<sup>st</sup>, 2023

Pursuant to article L-223-8 II of the French "code de Commerce" and 223-16 of the AMF's General Regulations.

Total number of shares	15,801,449	
Number of real voting rights* (excluding treasury shares**)	15,747,336	
Theoretical number of voting rights* (including treasury shares**)	15,778,249	

(\*) Class E preference shares are non-voting

(\*\*) pursuant to article 223-11 of the AMF's General Regulations



**About Median Technologies:** Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and iBiopsy<sup>®</sup>, our AI-powered imaging platform for the development of software as medical

devices (SaMD), help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label "Innovative company" by the BPI France and is listed on Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME). For more information: www.mediantechnologies.com

## Contacts

Median Technologies	Press - ALIZE RP	Investors - ACTIFIN
Emmanuelle Leygues	Caroline Carmagnol	Ghislaine Gasparetto
Head of Corporate Marketing & Financial Communications	+33 6 64 18 99 59	+33 6 21 10 49 24
+33 6 10 93 58 88	median@alizerp.com	ggasparetto@actifin.fr
emmanuelle.leygues@mediantechnologies.com		